NRBO NeuroBo Pharmaceuticals Inc

Price (delayed)

$4.34

Market cap

$21.29M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.22

Enterprise value

$5.49M

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of 4 drug candidates. The ...

Highlights
The debt fell by 8% QoQ
The EPS has soared by 82% YoY but it has decreased by 31% QoQ
The equity has dropped by 51% year-on-year and by 40% since the previous quarter
The quick ratio has declined by 38% since the previous quarter and by 17% year-on-year

Key stats

What are the main financial stats of NRBO
Market
Shares outstanding
4.91M
Market cap
$21.29M
Enterprise value
$5.49M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.11
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$16.58M
EBITDA
-$16.57M
Free cash flow
-$14.75M
Per share
EPS
-$3.22
Free cash flow per share
-$2.9
Book value per share
$2.05
Revenue per share
$0
TBVPS
$3.34
Balance sheet
Total assets
$17.02M
Total liabilities
$6.94M
Debt
$187,000
Equity
$10.08M
Working capital
$9.94M
Liquidity
Debt to equity
0.02
Current ratio
2.46
Quick ratio
2.34
Net debt/EBITDA
0.95
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-69.5%
Return on equity
-90.2%
Return on invested capital
N/A
Return on capital employed
-162.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NRBO stock price

How has the NeuroBo Pharmaceuticals stock price performed over time
Intraday
-3.77%
1 week
-12.5%
1 month
6.9%
1 year
5.57%
YTD
17.41%
QTD
-10.33%

Financial performance

How have NeuroBo Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$20.25M
Net income
-$16.58M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 33% QoQ and by 21% YoY
NRBO's operating income is down by 27% from the previous quarter and by 5% YoY

Growth

What is NeuroBo Pharmaceuticals's growth rate over time

Valuation

What is NeuroBo Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.11
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 82% YoY but it has decreased by 31% QoQ
The P/B is 90% above the last 4 quarters average of 1.1 but 63% below the 5-year quarterly average of 5.6
The equity has dropped by 51% year-on-year and by 40% since the previous quarter

Efficiency

How efficient is NeuroBo Pharmaceuticals business performance
The ROA has plunged by 53% from the previous quarter and by 4.8% YoY
The ROE has shrunk by 52% QoQ but it rose by 6% YoY

Dividends

What is NRBO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NRBO.

Financial health

How did NeuroBo Pharmaceuticals financials performed over time
NeuroBo Pharmaceuticals's total assets is 145% higher than its total liabilities
NeuroBo Pharmaceuticals's total assets has decreased by 46% YoY and by 25% QoQ
The quick ratio has declined by 38% since the previous quarter and by 17% year-on-year
The debt is 98% lower than the equity
NRBO's debt to equity has surged by 100% since the previous quarter
The equity has dropped by 51% year-on-year and by 40% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.